Hamlet Pharma Q3 Interim Report January – March 2022
Hamlet Pharma has reached important milestones during the third quarter of the fiscal year 2021-2022. We have successfully completed the dose-escalation part of the ongoing clinical study in bladder cancer and detected significantly stronger effects on the tumor in patients receiving increasing doses of Alpha1H.The tumors were strongly affected in patients treated with five times higher amounts of Alpha1H without an increase in side effects. These results are very encouraging for our continued development of the clinical program. We have intensified the collaboration with experienced